Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
Catalyst Pharmaceuticals (Nasdaq: CPRX) will release fourth quarter and full-year 2025 financial results after market close on February 25, 2026.
Rhea-AI Summary
Catalyst Pharmaceuticals (Nasdaq: CPRX) will release fourth quarter and full-year 2025 financial results after market close on February 25, 2026. Management will host a conference call and webcast on February 26, 2026 at 8:30 AM ET to discuss results and provide a business update.
Dial-in numbers are provided for US/Canada and international callers, and the webcast will be available in the Investors section at www.catalystpharma.com. A replay will remain on the website for at least 30 days following the event.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CPRX
In the Feb 11 session, CPRX declined 1.40%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings release date
- February 25, 2026
- Q4 and full-year 2025 financial results release after market close
- Earnings call date
- February 26, 2026
- Management conference call and webcast to discuss results
- Earnings call time
- 8:30 AM ET
- Scheduled start time of conference call and webcast
- US/Canada dial-in
- (800) 715-9871
- Domestic participant access number for earnings call
- International dial-in
- (646) 307-1963
- International participant access number for earnings call
Historical Context
-
Announced inaugural Catalyst Advocacy Scholars Summit with University of Notre Dame.
-
Planned presentation at 44th J.P. Morgan Healthcare Conference with webcast access.
-
Participation in Bank of America CNS Therapeutics Virtual Conference with webcast.
-
Ranked #304 on 2025 Deloitte Technology Fast 500™ on 249% revenue growth.
-
Announced appearance at Citi’s 2025 Global Healthcare Conference with webcast.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Company will Host a Conference Call and Webcast on Thursday, February 26, 2026, at 8:30 AM ET
CORAL GABLES, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2025 financial results after the market close on Wednesday, February 25, 2026.
Catalyst's management team will host a conference call and webcast on Thursday, February 26, at 8:30 AM ET to discuss the Company's financial results and provide a business update.
Conference Call & Webcast Details
| Date: | February 26, 2026 |
| Time: | 8:30 AM ET |
| US/Canada Dial-in Number: | (800) 715-9871 |
| International Dial-in Number: | (646) 307-1963 |
The webcast will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on the Catalyst website for at least 30 days following the date of the event.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., has been recognized by Forbes as one of America’s Most Successful Company in 2023, 2024, and 2025, and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024, its Quarterly Report on Form 10-Q for the third quarter of 2025, and its subsequent filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact Melissa Kendis, Catalyst Pharmaceuticals, Inc. (305) 420-3200 IR@catalystpharma.com Media Contact David Schull, Russo Partners (858) 717-2310 david.schull@russopartnersllc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.